




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、田野田野 教授教授哈醫(yī)大二院心內(nèi)科興奮收縮耦聯(lián)和心力衰竭的治療興奮收縮耦聯(lián)和心力衰竭的治療興奮收縮耦聯(lián)和心力衰竭的治療TOPICSp Excitation-contraction (EC) coupling Excitation Calcium Cycling Contractionp Alterations of E-C coupling in HFp Inotropic agents for HFExcitation-contraction coupling 興奮收縮耦聯(lián)和心力衰竭的治療The power of locomotion is that which contracts and
2、relaxes the muscles whereby the members and joints are moved, extended or flexed. This power reaches the limbs by way of the nerves and there are as many forms of power as there are of movement. Each muscle has its own peculiar purpose and it obeys the decree of the composite sense. Avicenna(1167124
3、8)William Harvey (1578 1657) He was an English medical doctor /physician, who is credited with being the first to correctly describe, in exact detail, the systemic circulation and properties of blood being pumped around the body by the heart. We shall designate the entire seque-nce of reactions: exc
4、itation, inward acting link, and activation of contra-ction by the term excitation-contraction coupling.ALEXANDER SANDOW,1952(New York University)Sandow A.Yale J Biol Med . 1952.25 (3): 176201 Cardiac excitationcontraction coupling is the process from electrical excitation of the myocyte to contract
5、ion of the heart (which propels blood out). The ubiquitous second messenger Ca2+ is essential in cardiac electrical activity and is the direct activator of the myofilaments, which cause contraction.Bers DM. Nature, 2002, 415(6868): 198-205.Excitation 興奮收縮耦聯(lián)和心力衰竭的治療The cardiac action potential A nota
6、ble difference between skeletal and cardiac myocytes is how each elevates the myoplasmic Ca2+ to induce contraction. In cardiac myocytes, the release of Ca2+ from the sarcoplasmic reticulum is induced by Ca2+ influx into the cell through voltage-gated calcium channels. Calcium Cycling 興奮收縮耦聯(lián)和心力衰竭的治療
7、Pictorial OF Calcium Cycling Ca+Ca+Ca+Ca+PlbCa+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Ca+Na+Na+Na+Ca+SERCASRRyRL-Type Ca+ChannelNa+/Ca+ ExchangerCa+SarcolemmaCa+Cardiac tissue and cells Conduct elec
8、trical waves Contract in response to an electrical stimulus(Guinea-pig ventricular cell)Cardiac tissueFunctionBSarcoplasmic Reticulum(SR)PLN and SERCAthe sites of interaction between PLN and SERCASodium-calcium exchanger(NCX) Two-way transporter “forward”mode “reverse”mode Na:Ca=3:1Ca release Coinci
9、des with activation of the contractile machinery Contraction 興奮收縮耦聯(lián)和心力衰竭的治療Sliding Filament TheoryA.F. Huxley1954EM evidence for sliding filament theoryThe micrograph shows myosin bound to actinThe molecular basis for myocardial contractionThin filament (Actin ,Tropom-yosin, Troponin) Thick filament
10、 (Myosin)Other proteinsChien, K.R., 1999ZZTitin28,000 amino acids (3MDa) the largest protein known in mammals.Titin MYOSINMYOSIN MW 480 kDaForms thick filamentsHydrolyses ATPInteracts with F-actin 300-400 myosin molecules per 1 filamentS1S1150 nmThick Filament ProteinsRLCELCATP Binding SiteActin Bin
11、ding SiteATP (Myosin) ADP + Pi + EnergyMyosin Head (S1) molecular motor of muscle contractionG-Actin F-ActinG to F actin MW 42 kDaThe blue and grey molecules are actin monomers (MW 42.000)Ken C. Holmes: Max-Planck-Institute Takeda, S. et al. Nature 424, 35 41, 2003 HCTnCHCTnIHCTnTTropomyosinTropomyo
12、sinbinding regionHypervariable regionCrystal Structure of Human Cardiac TroponinGordon et al. 2001Regulation of thin filament in contraction Muscle ContractionAlterations in E-C coupling in HF興奮收縮耦聯(lián)和心力衰竭的治療RyR2 channel leakHeart FailurePDE4D levelsloss of FKBP12.6RyR2 channel leakArrhythmia and prog
13、ression of heart failure.Jeffery D Molkentin. Nature Medicine 11, 1284 - 1285 (2005) PLNSERCA2a interactions in physiological and diseased cardiac functionSteven R. Houser. J Mol Cell Cardiol 32, 15951607 (2000)Inotropic Agents for HF興奮收縮耦聯(lián)和心力衰竭的治療Inotropic Agents and -blocker Digitalis Phosphodiest
14、erase inhibitor - adrenoceptor blockerDigitalis (200 years)Digilis purpureaPurple foxgloveWilliam Withering (1741 1799)Mechanism of ActionDigitalisOther study Some evidence suggests that the benefits of digitalis may be related in part to enzyme inhibition in noncardiac tissues. Inhibition of Na-K A
15、TPase in vagal afferent fibers acts to sensitize cardiac baroreceptors, which in turn reduces sympathetic outflow from the central nervous system. In addition, by inhibiting Na-K ATPase in the kidney, digitalis reduces the renal tubular reabsorption of sodium; the resulting increase in the delivery
16、of sodium to the distal tubules leads to the suppression of renin secretion from the kidneys.Thames MD. Circ Res. 1979;44:8 15.Ferguson DW et al. Circulation. 1989;80:6577.Torretti J et al. Am J Physiol. 1972;222:1398405.50403020100Placebon=3403Digoxinn=3397480122436Mortality %N Engl J Med 1997;336:
17、525Monthsp = 0.8N=6800NYHA II-IIIDIG trail (1997)ACC/AHA HF guideline 2009 Long-term use of an infusion of a positive inotropic drug may be harmful and is not recommended for patients with current or prior symptoms of HF and reduced LVEF, except as palliation for patients with end-stage disease who
18、cannot be stabilized with standard medical treatment (Stage D). (Class III, Level of Evidence: C) Continuous intravenous infusion of a positive inotropic agent may be considered for palliation of symptoms in patients with refractory end-stage HF(Stage D). (Class IIb, Level of Evidence: C) Phosphodie
19、sterase inhibitor The different forms or subtypes of phosphodiesterase were initially isolated from rat brains by Uzunov and Weiss in 1972 and were soon afterwards shown to be selectively inhibited in the brain and in other tissues by a variety of drugs The potential for selective phosphodisterase i
20、nhibitors as therapeutic agents was predicted as early as 1977 by Weiss and Hait. This prediction meanwhile has proved to be true in a variety of fields.Uzunov, P. and Weiss, B Biochim. Biophys. Acta 284:220-226, 1972 Weiss, B. and Hait, W.N.: Ann. Rev. Pharmacol. Toxicol. 17:441-477, 1977. Phosphod
21、iesterase-3 inhibitorPDEI cAMPAMPPDE3Yuan James Rao,(2009)Mechanism of action As a result of its high expression in both the vasculature and the airways, PDE3 was identified as a potential therapeutic target in cardiovascular disease and asthma. Augment myocardial contractility Relax vascular and ai
22、rway smooth muscle Inhibit platelet aggregation Induce lipolysisBARNES P.J.et al. Pharmacol. Rev. 1988;40:4984. MANGANIELLO V.C.,et al. Cell Signal. 1995;7:445455.“I wish I had my beta-blockers handy His landmark invention of propranolol in 1964 and the H2-receptor antagonist, cimetidine, in 1972 ea
23、rned him the Nobel Prize in Medicine in 1988.James W. Black - adrenoceptor Receptor BlockersMechanism of action Density of 1 receptors Inhibit cardiotoxicity of catecholamines Neurohormonal activation HR Antiischemic Antihypertensive Antiarrhythmic Antioxidant, AntiproliferativeN = 2289III-IV NYHAAC
24、C/AHA HF guideline 2009 Use of 1 of the 3 beta blockers proven to reduce mortality (i.e., bisoprolol, carvedilol, and sustained release metoprolol succinate) is recommended for all stable patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated . (Class I, Level of Evid
25、ence: A)When to start ? Patient stableNo physical evidence of fluid retentionNo need for I.V. inotropic drugs Start ACE-I / diuretic first Start Low, Increase Slowly Increase the dose every 2 - 4 weeksRisks of treatment Fluid Retention And Worsening HF(intensification of conventional therapy) Fatigu
26、re Bradycardia And Heart Block Hypotension (block alpha-1receptors)Review treatment (+/-diuretics, other drugs)Reduce doseConsider cardiac pacingDiscontinue beta blocker only in severe cases How should clinical deterioration be managed in patients who have been taking a beta blocker for long periods of time (more than 3 months)? if patients develop fluid retention, with or without mild symptoms, it is reasonable to continue the beta blocker while the dose of diuretic is increased. If the deterioration in clinical stat
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 水利工程造價(jià)與成本控制方案
- 基礎(chǔ)沉降分析與處理方案
- 防腐保溫施工過程中環(huán)境保護(hù)方案
- BIM技術(shù)支持下的建筑項(xiàng)目進(jìn)度監(jiān)控
- 2025年撫遠(yuǎn)市屬事業(yè)單位考試試卷
- 消防設(shè)施設(shè)備檢測與測試方案
- 建筑節(jié)能改造技術(shù)方案
- 渠道開發(fā)培訓(xùn)課件
- 在術(shù)后護(hù)理中的應(yīng)用
- 貼面的護(hù)理配合
- 防止返貧動(dòng)態(tài)監(jiān)測和幫扶工作手冊2022版
- 胃癌的影像學(xué)診斷
- 新疆維吾爾自治區(qū)國家級公益林管護(hù)辦法
- 唐山曹妃甸大宗物料長距離輸送綜合管廊工程海域使用論證報(bào)告書
- JJF 1915-2021傾角儀校準(zhǔn)規(guī)范
- GB/T 8017-2012石油產(chǎn)品蒸氣壓的測定雷德法
- GB/T 20633.2-2011承載印制電路板用涂料(敷形涂料)第2部分:試驗(yàn)方法
- 零星工程維修合同
- DB37-T 4328-2021 建筑消防設(shè)施維護(hù)保養(yǎng)技術(shù)規(guī)程
- 防盜門安裝施工方案50173
- 航空器緊固件安裝及保險(xiǎn)課件
評論
0/150
提交評論